November 08, 2016
RealTime Dynamix™: Rheumatoid Arthritis Q2
RealTime Dynamix: Rheumatoid Arthritis Q2 is the second instalment of the 2016 report series focusing on current and anticipated future trends in the RA treatment landscape. The Q2 report contains constant trended content, including current and future patient share, barriers to growth, industry contact rates, awareness and familiarity with products in development and sources of information about development compounds. Alternative variable content in Q2 includes rheumatologist statement agreements, brand analysis, impact of biosimilars, payer influence on prescribing, and patient compliance. Major in-line brands covered include Actemra, Cimzia, Enbrel, Humira, Orencia, Remicade, Rituxan, Simponi, and Xeljanz. RA pipe-line agents in the analysis include Baricitinib, Sarilumab, Sirukumab, and the recently approved biosimilar, Inflectra.